Advertisement

Topics

Pfizer: Lyrica Oral Solution CV Phase 3 Trial Meets Primary Endpoint

08:20 EDT 17 May 2018 | RTTNews

Pfizer Inc. (PFE) announced positive top-line results of a Phase 3 study examining the use of Lyrica or pregabalin Oral Solution CV as adjunctive therapy for partial onset seizures in pediatric epilepsy patients aged one month to less than four years.

Original Article: Pfizer: Lyrica Oral Solution CV Phase 3 Trial Meets Primary Endpoint

NEXT ARTICLE

More From BioPortfolio on "Pfizer: Lyrica Oral Solution CV Phase 3 Trial Meets Primary Endpoint"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pfizer
Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...